7-(2-aminoethyl)-4-methoxy-1,3-benzothiazol-2(3H)-one hydrochloride | 108773-33-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 7-(2-aminoethyl)-4-methoxy-1,3-benzothiazol-2(3H)-one hydrochloride
• 英文别名: 7-(2-aminoethyl)-4-methoxy-3H-1,3-benzothiazol-2-one;hydrochloride
• CAS: 108773-33-7
• 化学式: C₁₀H₁₂N₂O₂S*ClH
• 分子量: 260.744
• InChiKey: KXWZSUQIPHRRGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.52
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  89.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(2-aminoethyl)-4-methoxy-1,3-benzothiazol-2(3H)-one hydrochloride 在 氢溴酸 作用下， 反应 2.25h， 以60%的产率得到7-(2-aminoethyl)-4-hydroxy-1,3-benzothiazol-2(3H)-one hydrobromide
  参考文献：
  名称：

  Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent: benzothiazol-2-one 7-ethylamines

  摘要：

  Our interest in identifying D-1 and D-2 dopamine receptor agonists that are not catechols led us to extend previous studies with oxindoles by investigating analogues of dopamine, N,N-dipropyldopamine, m-tyramine, N,N-dipropyl-m-tyramine, and epinine in which the m-hydroxyl is replaced by the NH portion of a thiazol-2-one, oxazol-2-one, or imidazol-2-one group fused to the 2,3-position. These compounds were evaluated for their affinity and agonist activity at D-1 and D-2 receptors by using in vitro assays. Replacement of the m-hydroxy in N,N-dipropyldopamine with the thiazol-2-one group resulted in a dramatic increase in D-2 receptor affinity and activity compared to that of N,N-dipropyldopamine itself or that of the corresponding oxindole, 1. The resulting compound, 7-hydroxy-4-[2-(di-n-propylamino)ethyl]benzothiazol-2(3H)-one (4), is the most potent D-2 receptor agonist reported to date in the field-stimulated rabbit ear artery (ED50 = 0.028 nM). The benzoxazol-2-one (6), benzimidazol-2-one (5), and isatin (51) analogues showed D-2 receptor agonist potency similar to that of 1. The des-7-hydroxyl analogue of 4 (21) also has enhanced D-2 receptor activity compared to that of the corresponding oxindole, 8. 7-Hydroxy-4-(2-aminoethyl)benzothiazol-2(3H)-one, 27, a non-catechol, has enhanced D-1 and D-2 receptor activity in vitro compared to that of the corresponding oxindole, 7. In vivo, 27 increased renal blood flow and decreased blood pressure in the dog. However, these effects were mediated primarily by D-2 receptor agonist activity. This may be a result of the D-1 partial agonist activity of 27 coupled with its potent D-2 receptor activity.

  DOI：

  10.1021/jm00390a009
• 作为产物：
  描述：

  2-chloro-4-methoxy-7-<2-(trifluoroacetamido)ethyl>benzothiazole 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 以71%的产率得到7-(2-aminoethyl)-4-methoxy-1,3-benzothiazol-2(3H)-one hydrochloride
  参考文献：
  名称：

  Development of a Manufacturing Process for Sibenadet Hydrochloride, the Active Ingredient of Viozan

  摘要：

  A process for commercial manufacture of the dual D-2-beta(2) receptor agonist sibenadet hydrochloride has been developed. The process relies upon introduction of operationally simple chemistry at the final stages where two key intermediates are reacted to assemble the final molecule, isolated by crystallization. A nine-stage sequence for synthesis of the key amine hydrochloride intermediate was developed, and modifications to the original process are described. Major strategic improvements were made in definition of the final route to the "side chain" precursor molecule, the second key intermediate, hinging around a thiyl radical addition and subsequent high-yielding telescoped processes for synthesis of this highly crystalline benzoate ester. Development of these chemistries is discussed, together with some issues surrounding definition of the final validated commercial processes.

  DOI：

  10.1021/op049953y

文献信息

• Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
  申请人：Mammen Mathai

  公开号：US20050113417A1

  公开（公告）日：2005-05-26

  The invention is directed to compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7a , R 7b , W, G 1 , G 2 , a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  这项发明涉及到以下式I的化合物：其中R1、R2、R3、R4、R5、R6、R7a、R7b、W、G1、G2、a、b、c、d和m如规范中所定义，或其药学上可接受的盐、溶剂或立体异构体。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
  申请人：MAMMEN Mathai

  公开号：US20110034694A1

  公开（公告）日：2011-02-10

  The invention is directed to compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7a , R 7b , W, G 1 , G 2 , a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及公式I的化合物：其中R1，R2，R3，R4，R5，R6，R7a，R7b，W，G1，G2，a，b，c，d和m如规范中所定义，或其药学上可接受的盐、溶剂或立体异构体。本发明还涉及包括这些化合物的制药组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• 7-(2-aminoethyl)-1,3-Benzthia- or oxa- zol-2(3H) -ones
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0174811A2

  公开（公告）日：1986-03-19

  Compounds of formula (I): O-C2-8-alkanoyl derivatives thereof and pharmaceutically acceptable salts are described in which X is -S- or -0-, R1 and R2 are, each, hydrogen, C1-6-alkyl, allyl, benzyl, phenethyl, methoxyphenethyl or hydroxyphenethyl; and R3 and R4 are, each, hydroxy, hydrogen, halo, C1-3-alkyl or C1-3alkoxy. The compounds are dopamine agonists and have antihypertensive activity. Pharmaceutical compositions and methods of use are described, as are processes for their preparation.

  式(I)化合物： 其中 X 为-S-或-0-，R1 和 R2 分别为氢、C1-6-烷基、烯丙基、苄基、苯乙基、甲氧基苯乙基或羟基苯乙基；R3 和 R4 分别为羟基、氢、卤代、C1-3-烷基或 C1-3 烷氧基。这些化合物是多巴胺激动剂，具有抗高血压活性。本文描述了药物组合物和使用方法，以及其制备工艺。
• WEINSTOCK J.;GAITONOPOULOS D. E.;STRINGER O. D.;WILLIAM A., J. MED. CHEM., 1987, 30, N 7, 1166-1176
  作者：WEINSTOCK J.、GAITONOPOULOS D. E.、STRINGER O. D.、WILLIAM A.

  DOI：——

  日期：——
• US7345060B2
  申请人：——

  公开号：US7345060B2

  公开（公告）日：2008-03-18